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BACKGROUND

METHODS

CONCLUSIONS

22q11.2 deletion syndrome or DiGeorge syndrome
(DGS) is known to have diminished thymic function
or athymia with close 75% of cases having
concomitant cardiac anomaly. Given the reduction of
thymic tissue, it is expected that patients will have
reduced T-cell function and have a stunted cell
mediated immunity. Cardiac anomalies in DGS are
surgically corrected within the first year of life and
generally require the removal of thymic tissue to
better access the underlying cardiac structures. As a
result, these patients are often referred for
immunologic screen tests to monitor T-cell activity in
anticipation of development of a primary T-cell
deficiency. Interestingly, studies have shown that
only 2% of DGS patients have severe primary
immunodeficiency. A portion of these patients had
full athymia (previously known as complete DiGeorge
syndrome) and studies indicated a benefit for these
patients to receive thymus transplants on these
patients. The remainder of the population does show
decreased T cell subsets, specifically in the first two
years of life.

The study was comprised of a total of 46 patients diagnosed with 22q11.2 deletion syndrome via
FISH. 24 of these patients underwent a cardiothoracic surgery and 22 patients who did not undergo
any surgical procedure. Of the 24 patients who underwent cardiothoracic surgery, 9 patients had pre
and post-surgery data to directly compare changes in T cell lines.

It is likely that the majority of DGS patients do not
present with severe primary cell mediated
immunodeficiencies because their altered immune
system compensates with extrathymic T cell
differentiation. Maintenance of cell-mediated
immunity has been documented in DGS patients that
have undergone cardiac surgery in previous studies
but never prior to the age of two. A study that
assessed the long-term pattern of T cell populations
in DGS indicated that a deterioration of T-cell number
or function did not occur overtime. The results and
conclusions of this study warrant further investigation
with a larger population size. It would also be
beneficial to investigate T cell levels in patients who
underwent similar studies but where not diagnosed
with 22q11.2 (who likely have less extrathymic T cell
differentiation). However, from this novel
retrospective study, we can conclude that frequent
testing of T cell levels in the first two years of life, for
the reason of cardiac surgery being a stressor on cell
mediated immunity, is not indicated.

Among patients without surgery, there is significant decrease in CD4 percent from the baseline. We
found no significance changes between the first and at time points and second time points. Among
patients with surgery, we found no significance changes between the first and last timepoints
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This was a retrospective study conducted to evaluate
T cell function in patients with in the first two years
of life with 22q11.2 deletion syndrome and assess
the role of cardiothoracic surgery as stressor for
stunting cell mediated immunity. This was done by
measuring the difference between CD3, CD4, CD8,
CD19, NK cells, CD45RA, CD45RO levels (ARUP T-cell
subset panel 6) in the first 2 years of life in patients
who were diagnosed with 22q11.2 deletion
syndrome and comparing them to 22q11.2 deletion
syndrome patients who did not undergo a
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Our results showed that there was no significant difference in any of the T cell lines, with the Exception of CD4
in the control group. When comparing the pre and post T cell levels, there was no significant change in the lab
values. For those patients who had T cell levels that where below normal range, only 1 patient presented with
frequent infections and was immunocompromised (perhaps had true thymic aplasia with little extrathymic T
cell differentiation). Among the patients who did not undergo cardiothoracic surgery, there was a significant
decrease in CD4% from the baseline (P=0.03). This is likely due to a small population size. Removal of thymic
tissue did not play a significant role in alteration of the cell mediated immunity. When examining the T cell
levels past the age of two in the patients of this study, only one patient was truly immunocompromised with no
increase in T cell levels. This can be correlated to the general population of 22q11.2 deletion where 2% of the
population truly have a stunted cell mediated immunity.
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